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I. Introduction 
Infertility is usually defined, for a given couple, as the inability to achieve pregnancy 
within a reasonable duration. This time lag, two years in the guidelines provided by the World 
Health Organization (WHO), is often shorter in clinical practice, depending both on the 
impatience of the couple and on the celerity of the physician. Such a condition affects 
between 15% and 20% of the population in most countries, developed and developing. 
Among these couples, only a small proportion are affected by complete infecundity, i.e. 
sterility. These couples usually comprise between 3% and 5% of the population of 
reproductive age. In developed countries, the average fecundability (the "per cycle" 
probability of conception) generally fluctuates around an average value of 30%. Although the 
prevalence of unexplained infertility is decreasing, since the clinical and biological diagnostic 
procedures are becoming more efficient, conditions in which no factor explaining infertility is 
found in either the man or the woman account for between 5% and 10% of the cases in the 
varying surveys. Among the female factors, ovulation disorders (whatever their nature) and 
tubal alterations are the most prevalent conditions. In the great majority, partial or tubal 
alterations are the consequences of pelvic inflammatoiy disease following sexually 
transmitted diseases. Bacterial vaginosis associated with Gardnerella vaginalis, genital 
mycoplasmas and several anaerobic species, including Mobiluncus is the most prevalent 
cause of vaginal discharge, another cause of infertility (14). Over the last 30 years, there has 
been a large increase in the number of infertile patients found to have endometriosis. It is 
uncertain whether this is an actual increase or is simply a reflection of the more frequent use 
of laparoscopy in the investigation of the infertile couple. 
Endometriosis is a well-known disease in women of reproductive age. The functioning 
endometrial gland and stroma are situated outside the uterine cavity, and may be accompanied 
by pains in the small pelvis, infertility, dysmenorrhoea, dyspareunia and adnexal tumours. It 
is a benign, but usually persistent and progressive disease, second in incidence to myoma. In 
95% of the cases, it occurs in women between the menarche and menopause, whereas in the 
postmenopause a relationship seems to be evident with the oestrogen intake and hormone 
replacement therapy. Little is known about the real incidence. While an incidence of 20-50% 
is reported in the course of examinations by laparoscopy in consequence of infertility, an 
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incidence of 15-25% is mentioned during gynaecological operations performed on account of 
pain in the small pelvis (13,23,29,32,33,57). Endometriosis of the small pelvis is typically a 
disease of the age groups of 25-30, while the extragenital form affects mostly the age group 
35-40 (31). Although one-third of the patients are free of symptoms, in endometriosis the 
acute and chronic pain in the small pelvis is the most frequent complaint, which appears 
during the menstrual cycle and is associated with dysmenorrhoea and dyspareunia. The pain 
may be constant, on one or both sides, radiating towards the vagina, the groin, the buttocks or 
the perianal region (44). 
In most cases, laparotomy nowadays has replaced by operative laparoscopy, which 
plays the main role in the primary diagnosis of endometriosis, in the course of which the 
changes typical of endometriosis become apparent (4,10,16,23,61). In the diagnosis of the 
disorder, we can directly vizualise the classic endometriotic implant characterized by brown 
or black pigmentation and fibrosis, while direct biopsy can be performed on the non-
characteristic lesions, which facilitate the true diagnosis. Originally straightforward and easy, 
the diagnosis has developed into an art which requires a complete knowledge of the 
symptomatology of the various aspects, and above all an in-depth interpretation of all of the 
peritoneal anomalies. The most frequent sites of occurrence of the changes revealed during 
surgery are to be seen in Table I. 
Locations of endometriosis 
Ovaries 
Posterior cul-de-sac 
Broad ligament 
Uterosacral ligament 
Rectosigmoid colon 
Bladder 
Distal ureter 
Table VII 
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1. Peritoneal lesions 
It should be realized that the aspect of a peritoneal endometriotic and/or superficial 
ovarian lesion is the result of the combination of the red of the vessels, the black and pale-
brown of the intraglandular debris and the haemosiderin pigment (which we observe through 
a filter), formed by the peritoneum or the fibrosis, which is more or less opaque, depending on 
its thickness or age (8,9,29,56). 
1.1. Black or dark-blue lesions 
These are small black or dark-blue cystic lesions from one to several millimetres in 
diameter. They are covered and surrounded by a fibrous peritoneal reaction of varying 
thickness; this variation explains the difference in colour and their aspect, which is more or 
less retroperitoneal. Histologically, their black colour is due to the presence of debris in the 
lumen of the glands associated with the stroma and contained by the fibrosis. 
These black lesions are typical and are considered to be relatively inactive forms of 
endometriosis. However, it should be pointed out that they may be located anywhere and that 
they may only represent the tip of the iceberg, as recently shown by the work of the Koninckx 
team: macroscopically invasive lesions are similar to typical black lesions (43). It is therefore 
essential that these lesions can be identified, but their thickness needs to be evaluated to allow 
suitable treatment to be performed. 
1.2. White spots 
These thick peritoneal zones are white in appearance, due to the fibrosis by which they 
are formed. These white zones may contain small black dots, which are thinner zones of 
fibrosis, in which the glands and haemosiderin pigment content may be seen because of its 
transparency. The white zones have a fuzzy irregular star-shaped contour, as if the fibrosis 
surrounding the lesions was thinner at the edges. In this fibrosis, there are rarely glandular 
elements and they appear to be relatively inactive. Most authors consider these zones to be the 
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scar zones of previously active lesions, which of course may be widespread. The following 
should also be remembered: 
white spots are a consequence of peritoneal fibrosis and they may therefore be a 
consequence of other peritoneal aggressions; 
other, redder aspects which are more active are often to be found on the surface of 
these white zones, as if the lesions were once again becoming active or 
intraperitoneal, or as if these zones were the site of successive implantations. 
1.3. Excrescence 
According to Jansen in 1986, these lesions have the aspect, consistency and colour of 
the endometrium, as viewed by hysteroscopy (29). This tissue is translucent and shiny in 
appearance, and its colour and consistency are similar to those of the endometrium. 
1.4. Red lesions 
Red lesions can have the following aspects: 
red cysts or vesicles, due to the presence of many vessels that may be identified 
through their transparency and to which they owe the description "red flame-
like"; 
these red lesions have also been described as having the appearance of a polyp or 
a red bubble, whose contents are very rich in vessels and which explains this 
colour. 
These small cystic lesions may be as small as 200 A in diameter. They are therefore 
only just visible and their diagnosis requires close inspection of the peritoneum. Flat red 
lesions are much less common, but they may be active. 
1.5. Brown lesions 
Apart from the lesions situated below the whitish peritoneal layers that may be 
brownish in colour, brown lesions may have several different macroscopic aspects, ranging 
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from vesicles to quite often very dark-brown cysts on the surface of the peritoneum, the 
difference in colour from the red lesions probably being due to differences in the composition 
of the tissues which form them, the relative number of vessels and an increase in the 
intracystic debris or slightly different lighting conditions, which may contribute to the change 
in colour. Finally, the fiat brown lesions or brownish areas must also be mentioned, of which 
two types may be distinguished: 
Dark-brown areas whose aspect is very similar to when the thick, viscous contents 
of certain endometriomas form deposits on the surface of the peritoneum. 
Moreover, we suppose that some of these brown areas are a consequence of a 
recent rupture of an endometrioma, which is often later confirmed by questioning 
of the patient. As differences from the areas caused by recent surgical rupture, the 
two following elements may be distinguished: 
• these areas obviously cannot be treated by simple lavage, in the same way as 
deposits due to a recent rupture; 
• careful inspection shows that there are minute velamentous and vascular 
adhesions on the surface and the immediate surrounding areas of these lesions. 
Light-brown areas or Jansen coffee stains; these areas are therefore lighter in 
colour and their contour is often geographical. They are also thinner than the 
others, the glandular elements that they contain appear relatively inactive and they 
are few in number, and their colouring is explained by the presence of 
haemosiderin pigment. They are currently considered to be relatively inactive 
lesions. 
Finally, there are red-brown areas which are often much larger, which we have 
already described and whose higher vascular content has a higher level of activity. 
1.6. Light-coloured lesions 
These lesions are in fact light-coloured microvesicles, which are more visible in 
daylight under low lighting conditions. This is why they are often identified only when the 
level of lighting has been reduced, when a shutter is used, or on the edge of the video screen, 
where the light shines not directly, but tangentially. 
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1.7. Peritoneal defects 
These aspects were described by Sampson in the 1930s, and were reassigned to 
endometriosis by Chatman in 1981. The presence of endometriosis had in fact already been 
noted by DeBrux and Bret in their evaluation of the Allen and Masters syndrome. However, it 
was Chatman who showed in two successive studies that these peritoneal defects were much 
more common in patients with endometriosis (11). In fact, the implants are very often flat red 
lesions or red or light-coloured vesicles, which may be identified on the edge of or even 
inside the defect. The physiopathological mechanism of this association has not been fully 
identified: some consider that it is the presence of the defect which helps the endometriotic 
implant, while many other pathogenic theories suppose that the endometriosis could create 
them via the trauma induced in the peritoneum. 
1.8. Subovarian adhesions 
The adhesions in which the histological examination identifies endometrial glands are 
most often situated in the ovarian fossa, and thus join the ovary to the peritoneum on the rear 
face of the broad ligament. It should also be pointed out that these lesions are velamentous, 
vascular, petechial and often finer, more fragile and more uniformly red than post-infection 
adhesions. Their presence creates two problems: 
- the systematic biopsy of the vascular adhesions to make the aetiological diagnosis 
of the trauma which has induced them, as it is clear that macroscopy alone is 
insufficient to identify them reliably; 
- treating them requires coagulation or excision of these adhesions. 
These endometriotic velamentous vascular adhesions may be located in the ovarian 
fossa. 
1.9. Petechial zones 
Donnez described petechial zones and hypervascular zones (16). If endometrial glands 
may be identified in the peritoneal zones where several petechiae are situated, this aspect must 
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be interpreted with caution, as laparoscopic instruments can induce petechiae on the 
peritoneum, which is traumatized when it comes into contact with them. It is therefore 
essential to observe these fine anomalies on the peritoneum at the beginning of the operation, 
before the laparoscopic instruments have had an opportunity to modify the image obtained. 
Furthermore, it is also probable that the laparoscopic instruments induce petechiae more 
easily on inflamed and abnormal peritoneal zones than on perfectly normal zones. 
1.10. Hypervascularized zones 
These are red zones containing many dilated and sinuous vessels. These images may 
also be explained by red layers, which raises the possibility of confluent petechiae (25). 
2. Ovarian lesions 
Several elements of ovarian endometriosis need to be underlined: 
Lesions on the surface of the ovary can have atypical macroscopic appearances, 
such as peritoneal lesions, brown lesions, red lesions with brownish deposits and 
adhesions on the surface of the ovary. 
- Puncturing the ovary remains a classic act and is absolutely necessary in the 
laparoscopic work-up for pelvic endometriosis. Puncturing will in fact allow the 
endometrioma to be diagnosed in average or small ovaries. 
- Puncturing will be replaced by ovariolysis in many cases. In feet, many 
endometriomas are situated below the mesovarium on the anterior face of the 
ovary and will be discovered during the adhesiolysis of the upper part of the 
anterior face of the ovary. 
Further, the indications for puncturing the ovary may be guided by two signs, apart 
from the ovary adhering to the posterior face of the broad ligament, as follows: 
the presence of a star-shaped shrinkage zone on the ovary, especially if this zone 
is situated on the anterior face of the ovary; 
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the presence of a brown zone on the surface of the ovary is also a strong 
indication of the presence of endometriosis. 
Physiopathologically, it is as if the adhesions which form the anterior face of the ovary 
were drawing the anterior face of the ovary into contact with the broad ligament, with this 
ovarian adhesion preventing or limiting the utero-ovarian ligament from stretching due to the 
increased weight of the ovary. Finally, it should be remembered that puncturing with a fine 
needle is not a pathognomic element of the diagnosis. Experience from echographic punctures 
has provided confirmation that truly cystic lesions may be white as their contents are so thick 
that they cannot be sucked up through a needle. The following also needs to be stated about 
endometriotic cysts: 
their contents may be haemorrhagic, very close to or even identical to that of 
haemorrhagic luteal cysts, and this shows once again the necessity of a cytological 
and histological evaluation of all cysts which are "functional" or which are 
supposed to be when they are found during laparoscopy; 
chocolate fluid is very indicative, but not pathognomic, as around one-third of 
cysts with chocolate fluid contents are in fact luteal cysts, to the extent that 
Nezhat proposed that endometriotic cysts were a complication or a development 
of haemorrhagic luteal cysts. 
The ovarian endometrioma must always be considered first to be a tumorous 
pathology of the ovary. Endometriosis is sufficiently common to be associated with a 
tumorous pathology of different origin, which requires the same exploration as all ovarian 
pathologies (62). In addition, it is known that degeneration of the endometriotic lesions is not 
very common. It is not exceptional, however, and also justifies adopting a very strict attitude 
for the evaluation of endometriomas. 
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II. Aims of the investigation 
1. To determine the incidence of endometriosis due to infertility and examine the 
efficacy of gonadotropin releasing hormone (GnRH) analogue therapy in the 
treatment of the disease. 
2. To compare the efficacy of two GnRH analogues, nafarelin (Synarel, Syntex) 
and triptorelin (Decapeptyl-Depot, Ferring), and their side-effects during a 6-
month course of therapy and for another 6 months after the cessation of 
treatment. 
3. To compare the efficacy of assisted reproductive technology, intrauterine 
insemination (IUI) after GnRH analogue therapy in patients with endometriosis 
and patients who are free of this disease. 
4. To create a treatment protocol for infertile patients who have endometriosis. 
III. Patients, materials and methods 
On admission, a thorough gynaecological examination was performed in all of the 
patients included in the studies (colposcopy, cytology and bimanual, together with breast 
examination). Three months prior to the beginning of the trial, the duration of the menstrual 
cycle was found to be between 24 and 35 days. Each infertile patient complained of 
dysmenorrhea or dyspareunia. None of them was aware of any blood-clotting disturbance. 
The patients were given information on the need for laparoscopy, the administration of the 
required drugs and their potential adverse effects. They were asked to keep a therapy record, 
noting any complications, any symptoms or complaints, and details on the drugs taken. In 
addition, hyperandrogenic symptoms, mood swings and libido, together with any alteration in 
the frequency of headaches were noted. During the trial, patients in all groups were asked not 
to take any hormone products. The degree of intensity, frequency and tolerance of hot flushes 
were recorded on a visual analogue scale, whose data was based on the patients' complaints. 
The scale ranged from 0, meaning no pain or discomfort, to 10, at which the symptoms are 
intolerable. Each month we noted the body weight and blood pressure, and evaluated the 
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small-pelvic pain according to the results of a physical examinatioa No patient from either 
group took any steroids, and the medical history indicated that no patient was pregnant or 
lactating in the 3 months prior to the trial. We performed videolaparoscopy with 
chromopertubation prior to the start of the therapy. All the laparoscopics were performed 
under general endotracheal anaesthesia with a 10 mm diameter 30° laparoscope; in some 
patients, a biopsy was performed for histological confirmation of endometriosis. Where the 
diagnosis of endometriosis was uncertain during laparoscopy, histological examination of the 
biopsy sample confirmed the disease or disproved it. When endometriosis was diagnosed 
laparoscopically and/or histologically, the therapy was initiated in the first menstrual cycle 
after the operation. 
Several classification methods are available for defining the extent and the 
consequences of the disease, as well as for assessing the efficiency of the surgical or drug 
therapy. The score system of the American Fertility Society (AFS), modified in 1985, is 
currently the most widely accepted, and our classification was made on this basis (Table II) 
(44,48,76). The obtained scores were utilized to divide the patients into four stages (Table 
III). 
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The American Fertility Society (AFS) 
revised classification system 
ENDOMETRIOSIS < 1 cm 1-3 cm > 3 cm 
Peritoneum Superficial 1 2 4 
Deep 2 4 6 
Right ovary Superficial 1 2 4 
Deep 4 16 20 
Left ovary Superficial 1 2 4 
Deep 4 16 20 
Posterior cul-de- Partial 4 Complete 40 
sac obliteration 
ADHESIONS <1/3 1/3-2/3 >2/3 
Right ovary Filmy 1 2 4 
Dense 4 8 16 
Left ovary Filmy 1 2 4 
Dense 4 8 16 
Right tube Filmy 1 2 4 
Dense 4* 8* 16 
Left tube Filmy 1 2 4 
Dense 4* 8* 16 
* If the fimbriated end of the fallopian tube is completely enclosed, the point assignment is 
changed to 16. 
Table VII 
12 
AFS staging of endometriosis 
Stage I (minimal) 
Stage H (mild) 
Stage III. (moderate) 
Stage IV (severe) 
16-40 
6-15 
>40 
1-5 
Table III 
III. 1. Nafarelin study 
We performed 122 laparoscopics, indicated by infertility, chronic pain in the small 
pelvis, dyspareunia or ovarian cyst, with endometriosis as the underlying cause in 30 patients 
(25%). Following laparoscopy, all the 30 patients involved in our study were given GnRH 
treatment with nafarelin for 6 months, beginning from the first day of the first menstruation 
after the surgery. The initial dose of the drug was 2 x 200 pg per day intranasally, applied in 
both nostrils in turn in order to avoid the problems resulting from the possible local irritation. 
The use of nasal drops was not recommended between 1 hour before and after the 
administration of the drug because of vasoconstriction and resulting absorption failure. In the 
event of penetrating bleeding, the daily dose was raised to 800 pg. 
At the onset of the treatment, as well as at the end of the first, third, sixth, ninth and 
twelfth months, we checked the severity of dysmenoirhoea (Table IV), dyspareunia (Table V) 
and pain in the small pelvis (Table VI), relying upon the patient's complaints and the 
examination findings showing the extent of pressure sensitivity of the small pelvis (Table 
Within 2-4 weeks following the end of the drug therapy, control laparoscopy was 
carried out to examine the activity and the extent of the disease, taking the AFS classification 
into consideration. After the examination, we evaluated the changes in dyspareunia, in 
dysmenorrhea, in pain in the small pelvis and in pressure activity. 
VII). 
13 
Clinical findings in endometriosis 
Patient report 1 
Dysmenorrhea absent 
mild 
moderate 
severe 
not applicable 
no discomfort 
some loss of work efficiency 
in bed for part of one day, occasional 
interruption of work 
in bed for one or more days, 
incapacitation 
amenorrhoea 
Table IV 
Clinical findings in endometriosis 
Patient report 2 
Dyspareunia absent 
mild 
moderate 
severe 
not applicable 
no difficulty or pain 
tolerated discomfort 
intercourse painful to the point of 
interruption of intercourse 
avoids intercourse because of pain 
not sexually active, or prefers 
not to answer 
Table VII 
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Clinical findings in endometriosis 
Patient report 3 
Pelvic pain absent 
mild 
moderate 
severe 
no discomfort 
occasional pelvic discomfort 
noticeable discomfort for most of cycle 
requires strong analgesics; persistent during 
cycle or other than during menstruation 
Table VI 
Clinical findings in endometriosis 
Pelvic examination 
Pelvic tenderness absent no tenderness 
mild minimal tenderness on palpation 
moderate extensive tenderness on palpation 
severe unable to palpate because of tenderness 
Induration absent no induration 
mild uterus freely mobile, induration in the cul-de-sac 
moderate thickened and indurated adnexa and cul-de-sac, 
restricted uterine mobility 
severe nodular adnexa and cul-de-sac, 
uterus frequently frozen 
Table VII 
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III. 2. Nafarelin and triptorelin study 
133 patients with, laparoscopically-diagnosed endometriosis were treated with GnRH 
analogues. The efficacy and side-effects of nafarelin and triptorelin were compared during a 
clinical study of a 6-month course of treatment with a 6-month follow-up period. At the onset 
of the treatment, as well as after every month of the treatment cycle and the seventh, ninth and 
twelfth months, blood was taken to determine the serum levels of follicle-stimulating 
hormone (FSH), luteinizing hormone (LH) and 17p-oestradiol. There were 30 patients in the 
nafarelin group and 103 in the triptorelin group. In the first group, the patients' ages ranged 
from 18 to 42 years of age (average age 31 years), while in the second they ranged from 19 to 
45 (average 32 years). In the nafarelin group, 2 patients were given danazol, while in the 
triptorelin group, 11 patients were given progestogen and/or danazol (but more than 6 months 
prior to the start of the treatment). 
The initial dose of nafarelin was 400 pg, which was administered twice daily as an 
intranasal insufflation in both nostrils in turn. When breakthrough bleeding occurred, the dose 
of the drug was raised to an amount no greater than 800 pg. The use of nasal drops was not 
recommended before or after the nasal insufflation so as to avoid the occurrence of local 
vasoconstriction and a consequential absorption disorder. Each month, a dose of 3.75 mg 
triptorelin was administered intramuscularly (given in the deep muscle layer). 
III. 3. Triptorelin and ovulation induction study 
At our Department ovulation induction and homologous arteficial intrauterine 
insemination (HIUI) were performed, after GnRH analogue therapy, on 33 patients suffering 
from laparoscopically diagnosed endometriosis. The patients' ages ranged from 25 to 32 years 
of age (average âgé 28.3 years), while their body weights ranged from 65 to 80 kg (average 
75.6 kg). One patient was given danazol, but this was more than 6 months prior to the start of 
the treatment. Prelaparoscopic investigations included evaluation of the basal body 
temperature, and the vaginal discharge for microbiological culture. Blood was taken to 
determine the serum levels of FSH, LH, prolactin, testosterone and 17p-oestradiol on day 3 of 
the menstrual cycle, and again on day 21 of the cycle, to assess the progesterone level. The 
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hormones were measured by a chemiluminescent immunoassay with a DPC Immulite 
instrument. In the andrological examination of the partner, a spermiogram was taken and 
bacteriological testing of the seminal fluid and a postcoital test were performed. 3.75 mg 
triptorelin was administered intramuscularly each month for 6 months. 21 days after the last 
injection was given, ovulation induction was started according to the monofollicular protocol. 
50IU Puregon (pure FSH) was given daily for 2 days, and then from the third day, 1 ampoule 
of Humegon (75 IU FSH, 75 IU LH) was administered intramuscularly (Figure 1). On the 
fifth or sixth day of the stimulation, transvaginal ultrasonographic (TUS) examination was 
carried out. If the size of the dominant follicle and/or thickness of the endometrium did not 
reach the required level, the administration of Humegon was continued and the TUS 
examination was performed daily. If the dominant follicle reached a size of 20 mm and the 
endometrium was thicker than 9 mm (consisting of 3 layers), 10.000 IU hCG was given for 
luteinization after the serum level of oestradiol was determined. Wherever there was a danger 
of ovarian hyperstimulation, luteinization was not carried out (Table VIII). An intrauterine 
HIUI was performed 36 hours later. For homologous insemination, the concentration of sperm 
was determined from the homogenized ejaculate. The washing and enrichment of the sperm 
was carried out via "swim-up" technology. If the concentration reached 40x106 /ml, 3 ml of 
washing fluid (Spermfit, BIOMEDICAL) was added to 1 ml of ejaculate. If the concentration 
did not reach 40x106 /ml, 2 ml of washing fluid was added to 1 ml of ejaculate, the mixture 
was then centrifuged at 400 g for 10 minutes and the supernatant was drawn off. 1 ml of the 
medium was layered over a precipitate, care being taken not to agitate the precipitate. The 
material was incubated at room temperature for 45 minutes, and the sperm concentration, 
motility characteristics, the percentage, and the percentage of the normal forms were then 
repeatedly evaluated (Table IX). This procedure was carried out after the administration of 
hCG, but before the HIUI. 
Ovulation induction 
Monofollicular protocol 
g 
1 1 1 I I 1 
i W I U i l 
21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 
days after the last GnRH-analogue administration 
Figure 1 
50 I.U. FSH (Puregon) 
75 I.U. FSH (Humegon) 
75 I.U. LH 
10.000 I.U. hCG 
TUS (transvaginal 
ultrasonography) 
1 
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The danger of ovarian hyperstimutation syndrome 
DO NOT ADMINISTER hCG! 
in the ovary > 10 follicles 
10 follicles > 15 mm 
ovary size > 10 cm 
subjective symptoms (nausea, vomiting) 
serum oestradiol level > 6000 pmol/1 
Table VIII 
Spermium concentration by centrifugation 
"Swim-up" technology 
1. Analysis of the sperm 
2. Addition of wash fluid (Spermfit, Biomedical) 
3. Centrifugation (for 10 minutes at 400 g) 
4. Drawing-off the supernatant 
5. Sperm-concentrate medium 
6. Incubation 
7. Analysis of the supernatant: 
spermium concentration 
motility (%) 
motility characteristics 
supravital staining 
morphological examination 
Table IX 
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III. 4. Ovulation induction and body mass index study 
At our Infertility Outpatient Unit, 1144 married couples who attended between 1992 
and 1998 requested donor artificial intrauterine insemination (DIUI) treatment. After a 
thorough history-taking, the infertility examination was carried out on the basis of the criteria 
given by the WHO: determination of the prolactin and progesterone levels of the serum on 
days 21-23 of the menstrual cycle, hysterosalpingography and examination of the husbands. 
We excluded the possibility of endometriosis via the lack of typical symptoms; we did not 
perform laparoscopy. The Fallopian tubes of the wives were passable, the serum prolactin 
scores were in the normal range (below 580 mU/1), and their cycles proved to be ovulatory 
(serum progesterone above 19 nmol/1). Azoospermia or severe oligozoospermia (sperm 
concentration below 5 million/ml) was found in the husbands. The body mass index (BMI) 
was determined on the basis of the formula body weight (kg) / body height (m2). For 
extremely thin or obese patients, endocrinological examination was required in order to 
exclude the possibility of endocrine or metabolic diseases. During the preparation for DIUI, 
superovulatory treatment (clomiphen and gonadotropin) was carried out and the cycles of the 
wives were monitored. In the course of appropriate follicular maturation, which was proved 
by ultrasonographic folliculometry and by determination of the serum oestradiol level, 7500 
IU hCG was injected to provoke follicular rupture, and 24 hours later the DIUI was 
performed. The subsequent pregnancy was proved by immune pregnancy testing and TUS. 
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IV. Results 
IV. 1. Nafarelin study 
Before the start of the therapy, 20 of the 30 patients were in stage m according to the 
score system and 10 in stage II. After the treatment, 5 patients were in stage in, 6 in stage n, 
7 in stage I and 12 in stage 0 (Figure 2). According to the total AFS score system, which takes 
into consideration the adhesions, too, recovery was achieved in 11 cases and a partial 
improvement in 19 cases. Control laparoscopy revealed the total disappearance of the 
endometrial foci in 21 cases, partial disappearance in 8 cases, no change in 1 case and no 
aggravation in any of the cases. In the course of the study, a considerable improvement in 
dysmenorrhoea was found, with entire cessation in 22 cases. The pain in the small pelvis was 
considerably alleviated, or disappeared following a few aggravations in the beginning. There 
was a marked improvement or cessation of dyspareunia according to the subjective 
assessments of patients. From the beginning of the treatment until the end of the second 
month, there was a discontinuance in menstruation and no bleeding occurred throughout the 
course of the treatment. Following the cessation of the therapy, the normal menstruation cycle 
was restored within 56 days in 28 cases. Due to amenorrhoea in 2 cases, bleeding was induced 
with Norethisterone following day 56. Hot flushes gradually became more intensive from the 
third week of the treatment; in a few cases headaches, and in 2 cases numbness of the upper 
limbs with pain were found as side-effects. There was no need to interrupt the study before 
due time in consequence of side-effects or unexpected complications. 
IV. 2. Nafarelin and triptorelin study 
No significant differences were observed between the groups in the frequency of hot 
flushes during the 6-month course of treatment with a 6-month follow-up period (Figures 3 
and 4). The hot flushes started in the first month of the analogue therapy, and occurred several 
times a day; were mild at that time, but as the therapy progressed, the number and intensity 
increased. The number and intensity of the hot flushes were highest in the third month of the 
therapy and from the fifth month onwards a decrease in number was noticed. In the first 
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month following analogue therapy, reductions were observed in both their number and their 
intensity. The hot flushes completely disappeared from the second month on following the 
therapy. In the first month after the start of the medical therapy, the symptoms characteristic 
of menopause (colpoxerosis, nervousness, mood swings, and reductions in libido and in the 
size of the breasts, accompanied by hot flushes) appeared due to hypoestrogenism. As regards 
side-effects no significant difference was found between the two groups (Table X). 
Side-effects reported during GnRH analogue therapy (n=133) 
Synarel (n=30) Decapeptyl-Depot (n=103) 
nervousness 40% 38% 
mood swings 27% 26% 
hyperandrogenic symptoms 11% 10% 
decreased libido 35% 30% 
headache 13% 10% 
decreased breast size 18% 20% 
weight gain 6% 5% 
weight loss 3% 3% 
Table X 
There was no significant difference between the serum hormone levels in the two 
groups during and after the analogue therapy. We found that the GnRH analogue therapy 
decreased the serum FSH and LH concentrations, and the oestradiol level in all patients was 
in the postmenopausal range; after the therapy, all the values were within the normal range 
(Figures 5-7). At the end of the medical therapy, the ovaries were no longer inhibited, so the 
menopausal symptoms gradually became milder and eventually vanished. After an initial 
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exacerbation the symptoms characteristic of endometriosis showed an improvement in both 
groups as compared to those prior to the start of the treatment, which was a consequence of 
the effect of the analogue therapy. We found no significant complications in either therapy 
group. When the control laparoscopy was performed later, a significant improvement in the 
recovery from the disease was inferred. In the nafarelin group, 20 patients were in stage III 
and 10 in stage II at the beginning of the treatment. However, at the end only 5 patients were 
in stage HI, 6 in stage H, 7 in stage I and the remaining 12 in stage 0 (Figure 2). In the 
triptorelin group, prior to the start of the treatment 20 patients were in stage IV, 46 in stage 
IH, 31 in stage H and 6 in stage I, but after the treatment only 8 patients were in stage IV, 20 
in stage III, 22 in stage H and the remaining 26 in stage 0 (Figure 8). A marked improvement 
was also seen in those cases where the stage did not change after the treatment, as compared 
to the stage at the beginning of the treatment. 
IV. 3. Triptorelin and ovulation induction study 
The serum hormone levels were determined on days 3 and 21 of the menstrual cycle, 
within 2 months prior to the laparoscopy. In each case, normal hormone levels were detected. 
The laparoscopy revealed that 10 patients were in stage in, 18 in stage II and the remaining 5 
in stage I (Figure 9). Those patients whose tubes were shown to be penetrable via 
chromopertubation were included in the trial, while those with one or both Fallopian tubes 
occluded were excluded from the trial. GnRH analogues were naturally prescribed for the 
treatment of endometriosis. The andrological analysis in each case found normozoospermia. 
In 4 cases, the bacteriological test detected the presence of a pathogen, so targeted antibiotic 
therapy was given in accordance with the antibiogram. In 1 case, after the control test, 
targeted antibiotic therapy was repeatedly given until a negative result was attained. 
In the first month of the induction treatment, 5-8 (6.8 on average) ova reached a size of 
20 mm up to day 12 of the induction, which is in part due to the rebound effect following the 
inhibition. The follicle size ranged from 20 to 28 mm (24.4 mm on average). The intervention 
resulted in pregnancy in 15 (45%) cases, 3 of them being twin pregnancies. In 1 case, a 
spontaneous abortion took place in week 15 of pregnancy. 
AFS staging before and after Decapeptyl-Depot therapy (n=103) 
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IV. 4. Ovulation induction and BMI study 
The BMI of the women involved in the study varied between 16 and 36. On this basis, 
they were divided into 4 groups: A: 16-19 (thin), B: 20-24 (normal weight), C: 25-27 
(moderately overweight) and D: 28-36. (obese). Most of the women were in the normal BMI 
group. In the course of the superovulatoiy treatment, the induction was inefficient in 96 cases, 
and satisfactory follicle development did not occur. The risk of unsuccessful superovulatoiy 
treatment rise in a parallel with the shift from the ideal body weight (A: 1.5, C: 1.4, D :2.7) 
(Table XI) 
Distribution of the patients according to the BMI and the relative risk of 
unsuccessful ovulation induction in the different BMI groups 
BMI group Number of 
cases 
(n=1144) 
Unsuccessful 
ovulation induction 
(n=96) 
Relative risk 
(%) 
95% confidence 
interval 
A: 16-19 178 18 1.5 0.8-2.5 
B: 20-24 599 40 1 0.8-1.3 
C: 25-27 286 23 1.4 0.9-2.1 
D: 28-36 81 15 2.7 2.1-3.4 
Table XI 
As a result of DIUI carried out between 1992 and 1998, 412 pregnancies occurred, i.e. 
a success rate of 36%. Among the 412 pregnancies there, were 376 singlets, 29 twins, 6 
triplets and 1 quintuplet. In the latter case, at the request of the couple, pregnancy reduction 
was performed in gestational weekl 1, resulting in 2 live embryos. In spite of careful treatment 
and nursing, premature labour occurred in week 32 of the pregnancy. Caesarean section was 
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performed due to placenta praevia and live male twin foetuses weighing 1230 and 1390 g 
were delivered. From the pregnancies classified on the basis of the BMI, it can clearly be seen 
that DIUI can be applied most successfully in the case of a normal body weight (42%), 
whereas the pregnancy rate in overweight patients is only 21% (Table XII). 
Distribution of the pregnancies obtained by artificial donor 
insemination in the different BMI groups 
BMI group Number of cases 
(u=1144) 
Number of 
pregnancies 
% 
A: 16-19 178 50 28 
B: 20-24 599 251 42 
C: 25-27 286 92 33 
D: 28-36 81 19 21 
Table XII 
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V. Discussion 
Endometriosis (where the endometrial islets, which may be located at sites other than 
the uterine cavity, change due to the hormonal cycle) is a benign disease; 95% of the cases 
occur in women of reproductive age. In the postmenopause, the disease is usually related to 
the administration of oestrogen and hormonal replacement therapy, but it can be found in men 
as well (46). However, the disease should be regarded as an aggressive change because of its 
frequent recurrence. The true incidence of the disease is not known, but its rate has increased 
in the last few decades. This may be only an apparent increase, due to the development of 
laparoscopy and the detailed description of the typical and atypical lesions. In cases where the 
diagnosis of endometriosis is uncertain, histological examination (with an optical or electron 
microscope) of the biopsy sample may help in clarifying the disease (6,29). 
The underlying cause and the pathogenesis of the disease remain unclear, though 
several theories have been out forward in the last few years. 
1. Transport through the uterotubal route is the most widely accepted idea for the 
spread of the disease (18). According to the implantation theory of Sampson, endometriosis 
may develop in the course of retrograde menstruation, when viable endometrial cells get 
access to the abdominal cavity, adhere to the peritoneum and bring about the changes (63). 
The latest clinical data suggest that the theory of retrograde menstruation can account for 
most cases of the disease. During diagnostic laparoscopy in the perimenstrual period a bloody 
peritoneal discharge can be found in more than 90% of women with an intact uterine tube. 
2. According to Javert and to Scott et al., spreading through the lymphatic or blood 
vessels, respectively, also seems possible (30,66). Ridley et al. Demonstrated that the lesion 
can develop under experimental circumstances, as a result of an iatrogenic intervention, 
gynaecological operations including opening of the uterus, and Caesarean section (58). 
3. The endometrium and the peritoneum develop from the same coelom epithelium. As 
suggested by Meyer and by Rosenfeld et al., the peritoneal mesothelium turns into 
endometrial tissue in the course of metaplastic transformation (49,60). The transformation can 
take place spontaneously, but it may be promoted by chronic irritation due to the retrograde 
menstrual fluid. Muller cell remnants can be placed in the tissues of the small pelvis while 
25 
Miiller's duct is being developed, and in a few cases working endometrial gland and stroma 
can come into existence in response to the inducing effect of oestrogen. 
4. The most recent findings show that a disturbance of the immune system also plays a 
role in endometriosis. In this female disease, an elevated humoral immune response and 
macrophage activity are present while decreases in cell-mediated immunity and in T cell and 
natural killer cell (NK) activity are also evident (15,26). It has been possible for some time to 
use a variety of methods to detect organ-specific autoantibodies directed against the 
endometrium (47). 
5. Hereditary factors may also play a role in the disease. In the direct descendants of 
those suffering from this disease, the incidence is significantly higher than in the control 
group (28). 
If black or dark-blue lesions are surrounded by star-shaped scars in the visceral or 
parietal peritoneum in the small pelvis, we describe the case as endometriosis, though many 
other macroscopic formations were also identified as endometriotic changes in the 1980s, due 
to the development of laparoscopy techniques. Biopsies involving different techniques 
contribute to the confirmation of the diagnosis when the peritoneal change is atypical in 
appearance. Nevertheless, the diagnosis is easy to make in full knowledge of the different 
symptoms and the peritoneal and ovarian changes. 
V. 1. Nafarelin study 
30 patients were involved in the study, with control laparoscopy in each case. The 
regular menstrual cycles discontinued in the second month of the treatment. The adhesions 
and the peritoneal lesions were taken into consideration. A tremendous improvement occured 
in the symptoms. Dyspareunia ceased in 22 cases (73%). During therapy with nasal nafarelin, 
Henzl et al. found that the dyspareunia was eliminated in 87%, whereas in the control group it 
was eliminated in 69% in response to oral danazol treatment (27,34,36). The pelvic pain 
lessened considerably or ceased in response to nafarelin, similarly as following treatment with 
danazol (23). Within 6 months following the treatment, 7 pregnancies occurred (23%), which 
was similar to the 28% found by Henzl et al. (27). 
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In general, one-third of patients with endometriosis have no symptoms, but the usual 
symptoms are pelvic pain and dyspareunia, mostly accompanied by infertility. The pain can 
be acute or chronic, one- or two-sided in appearance, and can radiate to the vagina, inguinal, 
gluteal and perianal regions, typically beginning 1-2 days before menstruation and lasting 
throughout the flow. The pain may be related to intestinal and bladder activity, if these organs 
are affected. The intensity of the pain and the feeling of discomfort are not related to the 
severity of the disease. Rather, it is the location, the depth of the endometriotic implants, and 
their relation to the adhesions in the small-pelvis and abdominal cavities that are the 
determining factors. The depth of infiltration of the disease in the uterosacral ligaments and 
the rectovaginal septum is positively associated with pelvic pain and dyspareunia. Many of 
these women also complain of pain during bowel motion while menstruating (dyschezia). 
Pain in the iliac fossae and flank may indicate involvement of the ureters, which may result in 
haematuria and dysuria. Rectal bleeding ocurs in about 20% of patients who have significant 
bowel endometriosis. Very occasionally, if an endometrioma is ruptured or bleeds, acute 
abdominal pain is the presenting symptom. The disease may be found in abdominal scars 
from previous surgery (e.g. a Caesarean section), causing superficial cyclic pain, tenderness 
and swelling. 
Those in the age group 25-30 years generally suffer from small-pelvis endometriosis, 
while those in the age group 35-40 years suffer from the extragenital form. Extrapelvic 
endometriosis is estimated to occur in between 1% and 10% of patients with pelvic 
endometriosis. The disease has been reported to occur in almost all body structures, but the 
most common sites are the intestine, urinary tract, distal areas in the abdominal cavity, 
extrapelvic genital structures, lungs, skin and nervous system (31). Up to 50% of women with 
severe endometriosis have gastrointestinal forms, the most common sites being the 
rectosigmoid colon (50%), the appendix (15%), the small bowel (14%) and the coecum and 
colon (5%). The symptoms are diarrhoea, constipation, perimenstrual changes in bowel 
habits, rectal bleeding, pain on defecation, tenesmus, abdominal distension, small stools and 
colicky abdominal pain. Urinary tract endometriosis is thought to affect 1-4% of women with 
pelvic endometriosis; there have also been many cases without pre- or postoperative evidence 
of pelvic disease. Ureteral obstruction is associated with major morbidity; up to 30% of 
patients suffer a loss of kidney function, though renal endometriosis itself is extremely rare. 
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The bladder is the most common she of endometriosis in the urinary tract (80-90% of the 
cases), usually occuring in the trigone, the dorsal wall, at the uterovesicular juntion or 
transmurally. The ureters are involved in 10-15% of the cases, with the left being more 
commonly affected than the right. Urethral lesions are usually found in the distal third of the 
ureter below the pelvic brim. The symptoms are dysuria, superpubic pressure and back pain. 
The most common symptom of thoracic endometriosis is pneumothorax, followed by 
haemothorax, haemoptysis and asymptomatic lung nodule. Pleural lesions are more likely to 
cause pneumothorax or haemothorax. Haemoptysis is generally a result of lesions in the lung 
parenchyma. Diaphragmatic endometriosis may present as pain in the right upper quadrant or 
referred pain in the right shoulder. Endometriosis involving the skin is limited to the anterior 
abdominal wall at or below the umbilicus. Umbilical disease classically presents as a bluish 
tender mass, often associated with bleeding. The inguinal form presents as a painful mass. 
The overlying skin changes and cyclic symptoms vary. Endometriosis has been found in 
hernia sacs, in old inguinal scars and in the inguinal lymphatics. The most common site is the 
nerve in the pelvis. When sciatic pain occurs in relation to the menstrual cycle, it should 
suggest the presence of endometriosis. Involvement of the obturator nerve may produce pain 
and weakness in the proximal muscles of the thigh. Endometriosis has been reported in men 
undergoing treatment for prostate cancer by excision and orchidectomy and high-dose 
oestrogen therapy. The reduction in testosterone after removal of the testicles augmented by 
oestrogen therapy could account for these cases. For this reason, the pathological changes of 
other organs, together with the lesions of the interna] reproductive organs, should be taken 
into consideration in the differential diagnosis of the disease (Table XIII). 
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Differential diagnosis of endometriosis 
Abortion, complete 
Abortion, incomplete 
Abortion, inevitable 
Abortion, missed 
Abortion, septic 
Abortion, threatened 
Appendicitis, acute 
Bowel obstruction, large 
Bowel obstruction, small 
Colitis, diverticulitis 
Dysmenorrhea 
Gastritis/peptic ulcer disease 
Ovarian cysts 
Ovarian, torsion 
Pelvic inflammatory disease (PID) 
Pregnancy, ectopic 
Pregnancy, cervical 
Urinary obstruction 
Table XIII 
V. 2. Nafarelin and triptorelin study 
There was a noticeable decline in the symptoms of endometriosis. Dyspareunia was 
eliminated in 73% of the nafarelin group, as compared with 82% in the triptorelin group. 
Berquist et al. found that dyspareunia disappeared in 87% of the patients following triptorelin 
therapy, as compared with a 52% decrease in the control group, where a placebo was given 
(5,39). These results are similar to the findings of Gardo et al. who observed a clear reduction 
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or complete disappearance of the small-pelvic pain following nafarelin or triptorelin therapy 
together with danazol therapy (23). Similar results were obtained by Regidor et al., who 
reported a 20% pregnancy rate after buserelin acetate therapy. Seven (23%) patients in the 
nafarelin group became pregnant, as did 22 (21.4%) patients in the triptorelin group within 6 
months following the treatment (57). 
While it is easy to understand that advanced and severe endometriosis can cause 
disruption in the pelvis resulting in mechanical infertility, it is not similarly appreciated that 
minimal and mild endometriosis could have an impact on a woman conceiving and achieving 
a live birth. The link between endometriosis and infertility is based on the following 
observations: 
- endometriosis is prevalent in patients presenting with infertility; 
- the fecundity rate in women undergoing donor insemination is significantly 
reduced if they have endometriosis; 
-: the induction of experimental endometriosis in animals results in a decrease in 
fecundity rate. 
There are a number of possible mechanisms that can lead to infertility in patients with 
mild-to-moderate endometriosis (Table XIV). 
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Possible mechanism of infertility in patients with mild-to-moderate 
endometriosis 
Changes in peritoneal fluid 
- increase in volume 
- presence of interleukins and tumour necrosis factor 
- increased prostaglandin levels 
- increased number of macrophages 
Ovulation disorders 
- anovulation 
- hyperprolactinaemia 
- abnormal follicular genesis 
- premature follicular rupture 
- luteal phase defect 
- luteinized unruptured follicles 
Pelvic pain 
Immunological abnormalities 
- T cells 
- antigen-specific B cell activation 
- anti-endometrial antibodies 
- non-specific B cell activation 
Spontaneous abortion 
Implantation 
Table XIV 
The mechanisms that may form the basis for an association between endometriosis and 
infertility remain controversial. In addition to the anatomic damage that may occur, severe 
endometriosis can cause significant adhesions, which can distort the architecture. This 
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interferes with both the release of the oocytes and their transfer into the Fallopian tubes. 
Several studies have shown an increase in the volume of peritoneal fluid in women with 
pelvic endometriosis, but the correlation between fluid volume and fertility has not been 
consistent (1,2,74). Interleukins and tumour necrosis factor in the peritoneal fluid of 
endometriosis patients are involved in the inhibition of sperm motility and function, oocyte 
fertilization and embryo growth (17,70). The peritoneal fluid from women with endometriosis 
has a negative impact on the sperm motility, and the sperm binding to the zona pellucida has 
been shown to be reduced in vitro. Several groups have reported increased prostaglandin 
levels in the peritoneal fluid in endometriosis (1,74). Prostaglandins alter the tube motility and 
the collection of oocytes and can lead to luteinized unruptured follicle syndrome and corpus 
luteum defects or luteolysis. The number of macrophages in the peritonei fluid is increased in 
women with pelvic endometriosis. This is associated with the increased production of free 
radicals, which reduces the sperm motility (2). These macrophages are thought to be more 
activated, thereby affecting the rate of sperm phagocytosis and producing factors that might 
make the peritoneal fluid less hospitable to oocytes and sperm (50,51,73). Anovulation has 
been reported in 17-27% of patients with endometriosis, while others observed an increased 
occurrence of hyperprolactinaemia and effects within the peritoneal environment (68,71). A 
luteal phase defect, detected by out-of-phase endometrial development or asynchronous 
development of the endometrial glands and stroma, could be a consequence of abnormal 
follicular development, inadequate production of progesterone or a lack of response of the 
endometrium to progesterone (7). Luteinized unruptured syndrome has been described in 
monkeys with surgically induced periovarian endometriosis (64). Theoretically, a decrease in 
the number of LH receptors could be the underlying mechanism, but ultrasonographic studies 
have failed to show a consistent increase in incidence of this syndrome in patients with 
endometriosis. Pelvic pain can lead to a reduction in the frequency of intercourse and 
therefore reduce the likelihood of pregnancy. As endometriosis involves the transplantation of 
autologous endometrium and T cells are concerned with the rejection of homografts, changes 
in T cell function have long been suspected in endometriosis. Controversy exists, however, 
regarding the pattern of circulating leukocytes, as some, but not all, investigators have 
reported decreased numbers of lymphocytes. To add confusion, increased numbers of T cells 
and B cells, and higher CD4:CD8 ratios in the blood and peritoneal fluid have also been 
reported in women with endometriosis. Some researchers suggest that a subset of T cells is 
functionally deficient in women with endometriosis. Recently, a specific deficiency in 
lymphocyte-mediated cytotoxicity towards autologous endometrial cells was observed and 
was thought to be a result of an NK cell dysfunction. A lowered cytotoxic effect has been 
confirmed by other investigators, but not an NK cell dysfunction (52). A definitive 
mechanism by which altered T-cell function could cause infertility has not yet emerged. Anti-
endometrial antibodies directed towards endometrial cell antigens have been reported in the 
serum of women with endometriosis, but why they exist is controversial. Anti-endometrial 
antibodies have also been detected in women with a wide range of pelvic pathology 
(47,69,72). Non-specific B-cell activation, an autoimmune syndrome characterized by 
polyclonal B cell activation, has been suggested as a cause of infertility, thought the exact 
mechanism is unclear (3). An increased incidence of spontaneous abortion has been reported 
in patients with endometriosis, with a corresponding decrease after the endometriosis has 
been treated. Abnormalities in prostaglandin function could be the possible mechanism (54). 
In a non-randomized study of patients with endometriosis, two-thirds of whom had suffered a 
previous miscarriage, the pregnancy rate was similar whether these patients had had 
corrective surgery or not, but the miscarriage rate was higher in the group that had not been 
treated (55). The integrins are a group of compounds essential for cell adhesion. A deficiency 
of integrin av 3, a component of the embryo implantation cascade in the uterus, leads to a 
possible reduction in embryo implantation in women with early-stage endometriosis. 
However, this appears to be correctable when the disease is treated (59). 
V. 3. Triptorelin and ovulation induction study 
During the 6-month treatment with analogues, certain side-effects due to hypo-
oestrogenism emerged some 2-3 weeks after the first triptorelin injection. The menopausal 
symptoms gradually increased up to months 4 and 5 of the treatment, and a slight reduction 
was noticed in month 6. The ovulation induction therapy was started according to the 
mo no follicular protocol, on day 21 of the cycle after the last analogue injection was given. In 
the first month of the induction treatment, 5-8 (6.8 on average) ova reached a size of 20 mm. 
This number is significantly different from the numbers of mature follicles (3.9 and 4.2) 
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obtained after long-term therapy with GnRH analogue and hMG by Schmutzler and 
Leyendecker, and slightly lower than the results of Frydman, who obtained on average 8.4 
ova after the long-term protocol (21,37,45,65). Hyperstimulation was not observed during the 
trial, so luteinization was performed in each case. After homologue artificial therapy, 15 
(45%) patients became pregnant, 3 of these cases involving twins. This compares to 
efficiency rates of 25% and 27% following embryo transfer obtained by Leyendecker and 
Frydman (21,35,45), respectively. The 45% success rate is probably mostly due to the young 
age of the patients, the rebound effect following inhibition and the fact that no other causes of 
infertility apart from endometriosis were observed. This may be compared with the report by 
Koloszar, whose success rate was 36% following donor insemination, but in this study the 
patients' body weight was not ideal. When the patients' weight was normal, the success rate 
was similar (42%), but in the low and high body weight groups the rate was lower (28% and 
21%) (42). To sum up, the above course of treatment (6-month GnRH analogue therapy, the 
ovulation induction following the monofollicular protocol and HIUI) can be applied 
successfully in the treatment of infertility caused by endometriosis. 
The findings of the physical examination tell us about the extent of the disease. 
Usually, non-specific small-pelvic tenderness can be found in an examination. The tenderness 
is localized to the adnexal region if the ovaries are affected, while in the case of anaffected 
peritoneum the sacrouterine ligament can be painful and sensitive, or the tenderness is 
localized to the Douglas pouch. In the case of a "frozen pelvis", the uterus is in a fixed 
retroposition due to the extended adhesions and is accompanied by severe small-pelvic pain. 
If the ovarian endometriosis ruptures, acute abdomen may develop. However, if the 
gastrointestinal tract becomes affected due to the extended adhesions, obstructions can occur. 
Cyclic haemoptoea and pneumothorax can develop in extra-abdominal diseases (31). 
Urine analysis, a pregnancy test and, if required, evaluation of the serum P-HCG level 
and examination of a vaginal smear by electron microscopy may be of great assistance in the 
differential diagnosis, together with a detailed medical history and bimanual examination. A 
TUS examination may be useful in the assessment of the lesion in the small pelvis. The 
reliability of TUS depends on the nature of the lesions. In the detection of endometriomas, 
TUS is reported to have a sensitivity of 80% and a specificity of 95%. In contrast, the 
sensitivity of TUS in the detection of focal implants is poor and may be as low as 10%. 
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Typically, endometriomas are visualized as predominantly cystic masses with thick walls, 
often with diffuse acoustic enhancement or scattered internal echoes and may contain septae, 
dependent echoes or fluid levels. Computerized tomography and magnetic resonance imaging 
(MRI) are more sensitive in detecting small-pelvic lesions than an ultrasonographic scan, but 
their uses are limited in the case of multiple small-pelvic endometriosis. MRI detects 
endometriomas, ovarian adhesions and extraperitoneal masses. It may be useful for revealing 
changes in the size and number of endometriotic lesions during therapy, for detecting the 
invasion of the nerves, as in sciatic endometriosis, and for identifying abdominal wall lesions. 
MRI findings do not correlate with the stage of the disease. Taking unadulterated (native) 
abdominal X-ray pictures is not recommended until other diagnostic procedures suggest that 
there is an intestinal obstruction. Three serum immunoassays have been tried in the diagnosis 
of endometriosis: CA-125, placental protein 14 (PPM) and antibodies to endometrium. Of 
these, CA-125 shows the most promise. CA-125 is an ovarian epithelial tumour antigen that is 
detected by a monoclonal antibody designated OC-125. The incidence of elevated CA-125 
levels increases with the severity of the disease, and the mean concentrations clearly correlate 
with the disease stage. However, since the CA-125 levels are not elevated in mild forms of 
endometriosis, and are elevated during and immediately after menstruation, CA-125 is not 
useful as a screening test. It could, however, be valuable in monitoring the effects of therapy. 
CA-125 measurement has been successfully used in conjunction with other examinations (e.g. 
TUS) (19,53,73). 
Hormonal therapy has been the main medical treatment for endometriosis for half a 
century. In the 1940s and 1950s, diethylstilboestrol and methyltestosterone were used, but 
these therapies in the treatment of the disease should now be given only a historical mention, 
as their use is no longer accepted, due to the frequent occurrence of side-effects. Kistner, in a 
paper published in 1958, reported on pseudopregnancy, which generally developed after high-
dose oestrogenic-progestogenic therapy. He achieved significant results in reducing the 
medical complaints (41). After the use of antigonadotropin therapy by Greenblatt in 1971, it 
was applied as a standard drug in measuring the effectiveness of the treatment of 
endometriosis (24). Danazol is a synthetic by-product of testosterone, with a half-life of 4.5 
hours. Peak levels are reached 2 hours after oral ingestion and it is undetectable after 8 hours. 
It is metabolized in the liver, and the principle metabolite, methylethisterone, exhibits mild 
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progestogenic and androgenic activity. Danazol has a direct effect on steroidogenesis, acting 
on cholesterol cleavage enzymes and on intracellular steroid receptors. It has an indirect 
action by decreasing the GnRH pulse frequency, which may suppress ovulation. The most 
common side-effects are related to the hyperandrogenic state: weight gain, oily skin and hair, 
nausea, acne, muscle cramps and hirsutism. Deepening of the voice, though uncommon, is 
irreversible. Hypo-oestrogenic side-effects, such as hot flushes, decreased breast size and 
reduced libido, may also occur. Danazol has multiple metabolic side-effects, the most 
important of which relate to the blood cholesterol. It decreases HDL and increases LDL 
levels, which must be taken into account as the drug is given for long periods (6-9 months). 
Its use should be avoided in women with a history of liver disease. Gestrinone, a progesterone 
agonist/antagonist, which is a 19-nortestosterone derivative, was used primarily as a long-
term contraceptive drug (12). The actions of gestrinone result in amenorrhoea and endometrial 
atrophy, similar to other androgen steroid analogues (e.g. danazol). It acts both centrally and 
peripherally to reduce oestradiol and obliterate the midcycle LH surge. It has a long half-life, 
allowing oral administration 2-3 times weekly. Gestrinone has fewer androgenic symptomatic 
and metabolic effects as compared with danazol, and fewer hypo-oestrogenic side-effects. 
Operative castration and subsequent hypoestrogenism would be the real solution in the 
treatment of the disease, but this is out of the question with young women of reproductive 
age. The development of GnRH analogues which reversibly inhibit the function of the ovary 
in a hormonal way, was a breakthrough in the treatment of the disease (14,50). GnRH is a 
decapeptide produced by the arcuate nucleus of the hypothalamus and is secreted episodically 
into the pituitary circulation to regulate the release of LH and FSH. GnRH can be metabolized 
by pituitary endopeptidases (cleavage at positions 5-6 and 6-7) and carboxyamide peptidase 
(cleavage at position 9-10). These degradative steps inactivate the molecule and are 
responsible for the short, 2- to 8-minute half-life of GnRH. Nafarelin acetate and triptorelin 
are analogues of GnRH in which the amino acid sequence is ranged. This results in GnRH 
analogues with high affinity for the GnRH receptor and a very long half-life (240 minutes), 
because the synthetic derivative is more resistant to the effect of endopeptidase. Because of 
the long half-life and enhanced potency of the GnRH analogues nafarelin and triptorelin, 
administration of these compounds results in prolonged and continuous occupancy of the 
pituitary GnRH receptor. The effects of nafarelin and triptorelin administration are similar to 
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those of a continuous high-dose infusion of GnRH. The analogue administration results in an 
initial phase in which there is release of LH and FSH. This is followed by a protracted state of 
decreased gonadotropin secretion. The second phase of this action of the analogues ultimately 
leads to a hypogonadal state, with a marked decrease in ovarian oestrogen production. The 
mechanism by which nafarelin and triptorelin produce an initial agonist effect (initial release 
of LH and FSH), and then a paradoxical and marked decrease in LH and FSH secretion, is not 
known at the molecular level. Two proposed mechanisms are desensitization and down-
regulation. Desensitization refers to an uncoupling of the activated GnRH receptor from the 
intracellular mediators of signal transduction. Down-regulation refers to a decreased number 
of unoccupied cell-surface GnRH receptors. In contrast with danazol, the only protein with 
which nafarelin and triptorelin interact is the pituitary GnRH receptor. The decreases in 
pituitary LH and FSH secretion produced by these analogues result in decreases in ovarian 
oestradiol and progesterone production. Virtually all of the effects of the analogues are caused 
by the decreased ovarian oestradiol and progesterone production. As noted previously, 
agonists truly display "molecular specificity", interacting with the pituitary GnRH receptor 
and few other proteins. In contrast, danazol interacts with at least a dozen proteins, including 
enzymes of steroidogenesis, multiple classes of steroid receptors, and circulating steroid-
binding proteins. The endocrine pharmacology of agonists are the best understood by 
comparing them with danazol. Nonetheless, the clinical profiles of women taking danazol 
appear to be quite different from those of women taking the GnRH agonist. Specifically, 
patients treated with danazol tend to have a greater degree of weight gain and bloating than 
have women treated with agonists. Further, women treated with danazol have a higher 
incidence of deepening of the voice, acne, oily skin and unwanted growth of facial hair. In 
contrast, the GnRH agonists tend to be associated with a higher incidence of hot flushes, 
vaginal dryness and decreased libido. The effects of the hormones employed in the treatment 
of endometriosis are listed in Table XV. 
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Endocrine effects of hormones used in the treatment of endometriosis 
Gonadotropic Function of Endometrium Other effects 
secretion the ovary 
Pseudopregnancy 
(oestrogen/progestogen) 
inhibition inhibition decidual oestrogenic, 
progestogenic 
Progestogen variable 
inhibition 
variable 
inhibition 
decidual progestogenic 
Pseudomenopause 
(danazol) 
inhibition inhibition atrophy androgenic, 
anabolic, 
immunological 
GnRH agonists short 
stimulation, 
then 
inhibition 
short 
stimulation, 
then 
inhibition 
atrophy menopausal 
symptoms 
Table XV 
V. 4. Ovulation induction and BMI study 
It is well known that ovulatory disorders are more frequent in lower and higher body 
weight groups. Furthermore, the efficiency of ovulation induction with clomiphen citrate can 
be considerably enhanced of decreasing a pathologically high body weight, or increasing a too 
low weight, towards the ideal condition. The ideal body weight can ensure a favourable 
interior environment for the function of the endocrine system; additionally, a pathological 
body weight may play a role in luteal failure (40). In order to maintain the ideal body weight, 
the intact functioning of certain areas of the hypothalamus is necessary. It has been found in 
animal experiments that, following lesions of the medial preoptic part of the hypothalamus, 
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the body weight increases and an ovarian malfunction occurs. Furthermore, in female 
animals, oestrogen withdrawal by castration leads to an increased food intake. The inhibitory 
effect of oestrogen on nutrition takes place through the neuropeptide-Y and the galanin 
peptidergic system (22). When a total of 1144 infertile women were treated by DIUI, 
unsuccessful ovulation induction was found in 96 cases. The obese women (BMI: 28-36) had 
a relative risk of unsuccessful ovulation induction of 2.7 (95% CI = 2.1-3.4) as compared with 
women with a lower or normal body weight (BMI: 20-24). The effect was smaller in women 
with a BMI of 25-27 or <19 (RR = 1.4, 95% CI = 0.9-2.1 and RR = 1.5, 95% CI = 0.8-2.5, 
respectively). During DIUI treatment, 412 pregnancies occurred. The pregnancy rate achieved 
by insemination was 28% (50 pregnancies in 178 cases, BMI 16-19), 42% (251/599, BMI 20-
24), 33% (98/286, BMI 25-27) and 21% (19/81, BMI 28-36), in the different BMI groups. 
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VI. Conclusions 
Nafarelin and triptorelin are synthetic GnRH analogues which are 200 times as 
effective as the endogenous protein. They stimulate the release of LH and FSH from the 
anterior lobe of the pituitary, but this effect shows a gradual decrease in continuous 
administration as a result of desensitization of the pituitary due to the down-regulation of the 
receptors. The treatment aims at the pharmacological manipulation and changing of the milieu 
in the small pelvis. In response to continuous administration, nafarelin and triptorelin inhibit 
the pituitary - ovary axis and the evoked hypooestrogenic condition proves to be very efficient 
in the therapy of the endometriosis of the small pelvis, with rapid decreases pain and other 
symptoms. The induced oestrogen deficiency condition is tolerated by the patients quite 
satisfactorily. 
In conclusion, we can state that nafarelin and triptorelin can be successfully applied in 
the treatment of endometriosis and its symptoms (dysmenorrhoea, dyspareunia and 
infertility). Besides having the advantage of a practical depot formulation which ensures a 
sustained and continuing release of the analogue, triptorelin provides a very good suppression 
of gonadal steroidogenesis. We found that the GnRH analogue therapy decreases the serum 
FSH and LH concentrations; the oestradiol levels in all patients, were initially in the 
postmenopausal range, were all within the normal range after the therapy. In fact, although 
this therapy is often referred to in the literature as "medical castration", it has been 
hypothesized that complete inhibition of gonadal steroidogenesis is rarely achieved with the 
doses of agonists in current use. In the trials, significant side-effects other than symptoms of 
an oestrogen deficiency (which seem to be acceptable and which promptly disappeared after 
the suspension of agonist therapy) were not observed either during the treatment or in the 
follow-up period. A cyclic pituitary-ovarian function returned within 2 months of the end of 
therapy. In no patient did the trial end before the set period due to side-effects or unexpected 
complications. The patients overcame the reversible hypoestrogenism quite well. 
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Results of the investigation 
1. We sought to explain the incidence of endometriosis due to infertility in our 
region, the clinical application and efficiency of nafarelin in cases of endometriosis diagnosed 
during Iaparoscopy, and the decline in activity and expansion of the disease in the course of 
the 6-month therapy. We performed 122 laparoscopics in the investigation of infertility and 
found endometriosis to be the underlying cause in 30 patients (25%). After treatment of the 
adhesions and the peritoneal lesions was taken into consideration, there was a marked 
improvement in the symptoms. 
2. We compared the clinical applicability, the efficacy, and the usual and 
unexpected side-effects of two GnRH analogues, nafarelin and triptorelin, and the reduction 
in the activity and spread of the disease after the 6-month course of treatment. 133 patients 
with laparoscopically-diagnosed endometriosis were treated with the GnRH analogues. No 
significant differences were observed between the groups in the frequency of hot flushes. The 
hot flushes disappeared completely from the second month on following the therapy. In the 
first month after the start of the medical therapy, symptoms characteristic of the menopause 
(colpoxerosis, nervousness, mood swings, a reduction in libido and a decrease in the size of 
the breasts, accompanied by hot flushes) appeared due to hypoestrogenism. As regards side-
effects, no significant difference was found between the two groups. There was no significant 
difference between the two groups in the serum hormone levels during and after the analogue 
therapy. We found no significant complications with either therapy formulation. There was a 
noticeable decline in the symptoms of endometriosis. Dyspareunia vanished in 73% of the 
nafarelin group, as compared with 82% in the triptorelin group. 
3.1. We examined the efficiency of HIUI following ovulation induction. This was 
performed, after triptorelin therapy, in patients where laparoscopically diagnosed 
endometriosis had elucidated the cause of their infertility and pelvic pain. At our Department, 
ovulation induction and HIUI were performed after GnRH analogue therapy in 33 patients 
with laparoscopically diagnosed endometriosis. The intervention resulted in pregnancy in 15 
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(45%) cases, of which 3 were twin pregnancies. In 1 case, a spontaneous abortion took place 
in week 15 of the pregnancy. 
3.2. We sought a correlation between the female body weight and the efficiency of 
DIUI, with special regard to successful superovulatory treatment and ensuing pregnancies. At 
our Infertility Outpatient Unit, 1144 married couples attending between 1992 and 1998 asked 
for Dim treatment. As a result of DIUI between 1992 and 1998, 412 pregnancies occurred, 
which means a success rate of 36%. Among the 412 pregnancies, there were 376 singlets, 29 
twins, 6 triplets and 1 quintuplet. When the pregnancies were classified on the basis of the 
BMI, it could be seen clearly that DIUI can be applied most successfully in cases with a 
normal body weight (42%), while the pregnancy rate in overweight patients is only 21%. 
In the first month of induction treatment, 5-8 (6.8 on average) ova reached a size of 20 
mm in both groups. Hyperstimulation was not observed during the trial, so luteinization was 
performed in each case where the ovulation induction was successful. We established that 
there was no significant difference in pregnancy rate between the two IUI-treated groups, who 
had or who were free of endometriosis, but the body weight was in the normal range. After 
GnRH analogue treatment, ovulation induction and IUI therapy, 15 (45%) patients became 
pregnant as compared with ovulation induction and IUI treatment, where the success rate was 
36%, but in this study the patients body weight was not ideal. When the patient's weight was 
normal, the success rate was similar (42%), whereas in the low and high body weight groups 
the rate was lower (28-21%). 
4. We suggest a treatment protocol for infertile patients who have endometriosis 
that calls for remove al of the endometriomas during laparoscopy, and decrease of the number 
of adhesions and endometrial plaques; the patients have to start ovulation induction as soon as 
possible, after the analogue therapy, and to supplement it with other assisted reproductive 
technology if required, because the success rate was significantly lower (21.8%) if we did not 
use ovulation induction management after the analogue therapy. We conclude that the 
analogue therapy and the continuous ovulation induction with monofollicular protocol and 
IUI represent a good therapeutic option in the management of infertility due to endometriosis. 
We found that 85% of the pregnancies occurred in the first two cycles. 
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To sum up, the above course of treatment (6-month GnRH analogue therapy, and 
ovulation induction following the monofollicular protocol and HJI) can be applied 
successfully in the treatment of infertility caused by endometriosis. Further efforts must be 
made to achieve and maintain the ideal body weight, since in this way the efficiency of 
ovulation induction and IUI can be enhanced. 
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